TCR2 Therapeutics

URI: https://gptkb.org/entity/TCR2_Therapeutics

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:biotechnology
gptkbp:acquiredBy	gptkb:Kite_Pharma
gptkbp:acquisitionYear	2023
gptkbp:CEO	gptkb:Garry_Menzel
gptkbp:clinicalTrialPhase	gptkb:gavo-cel_(TC-210)
gptkbp:developedBy	T cell therapies
gptkbp:focusesOn	oncology immunotherapy gene therapy
gptkbp:foundedYear	2015
gptkbp:founder	gptkb:Patrick_Baeuerle
gptkbp:headquartersLocation	gptkb:Cambridge,_Massachusetts,_United_States
https://www.w3.org/2000/01/rdf-schema#label	TCR2 Therapeutics
gptkbp:industry	gptkb:biotechnology
gptkbp:listedOn	gptkb:NASDAQ
gptkbp:notableProduct	gptkb:TRuC-T_cells
gptkbp:publiclyTraded	yes
gptkbp:specializesIn	gptkb:T_cell_receptor_fusion_construct_(TRuC)_platform
gptkbp:stockSymbol	gptkb:TCRR
gptkbp:target	solid tumors
gptkbp:website	https://www.tcr2.com/
gptkbp:bfsParent	gptkb:Jean-François_Formela gptkb:Ropes_&_Gray_LLP
gptkbp:bfsLayer	7